← Eichor
Study identifier: NCT07730073 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy of LSVT-LOUD Therapy on Voice, Speech, and Quality of Life in Parkinson's Disease

Condition: Parkinson's Disease (PD)  ·  Sponsor: Atlas University

PhaseNA
Planned participants24
Who can joinAll sexes, 40 Years to 80 Years
Healthy volunteersNo

About this study

Parkinson's disease often causes speech and voice impairments, such as reduced vocal loudness and decreased speech intelligibility, which significantly impact the quality of life for patients and their families. The Lee Silverman Voice Therapy-LOUD (LSVT-LOUD) is a specialized, evidence-based speech therapy protocol designed to improve vocal function. This study investigates the effectiveness of the LSVT-LOUD protocol in Turkish-speaking individuals with Parkinson's disease. The research evaluates objective changes in vocal loudness and speech quality, as well as the subjective therapy experiences of participants. By analyzing both clinical outcomes and patient feedback, this study aims to contribute to the clinical application and adaptation of LSVT-LOUD for the Turkish-speaking population

This description comes directly from the study's public registry record.

Talk to the study team

Ayşe Nur Koçak, Master of Science  ·  +90 549 650 20 60  ·  aysenur.kocak@atlas.edu.tr

Always discuss trial participation with your own doctor first.

Locations (1)

Atlas UniversityKâğıthane, Istanbul, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07730073